Yale Cancer Center Research Helps Expand NCCN Guidelines For Ovarian Cancer
January 06, 2023
January 06, 2023
NEW HAVEN, Connecticut, Jan. 6 (TNSjou) -- Yale School of Medicine issued the following news:
Results from a recent Yale Cancer Center Phase II trial studying ixabepilone and bevacizumab vs ixabepilone alone in platinum resistant ovarian cancer patients have led to the combination added as a Category 2B recommended regimen in Ovarian Cancer (Version 1.2023) of the National Comprehensive Cancer Network (NCCN) Guidelines(R).
The results of the study, which was authored by . . .
Results from a recent Yale Cancer Center Phase II trial studying ixabepilone and bevacizumab vs ixabepilone alone in platinum resistant ovarian cancer patients have led to the combination added as a Category 2B recommended regimen in Ovarian Cancer (Version 1.2023) of the National Comprehensive Cancer Network (NCCN) Guidelines(R).
The results of the study, which was authored by . . .